Tanvex BioPharma, Inc. (TPE:6541)
Taiwan
· Delayed Price · Currency is TWD 56.70
+0.10 (0.18%)
Jul 11, 2025, 1:30 PM CST
Tanvex BioPharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | -1,429 | -1,382 | -2,137 | -1,641 | -1,543 | -2,104 | Upgrade
|
Depreciation & Amortization | 311.35 | 287.56 | 323.59 | 280.01 | 241.43 | 215.83 | Upgrade
|
Other Amortization | 2.31 | 1.48 | 1.24 | 1.55 | 2.15 | 4.58 | Upgrade
|
Loss (Gain) From Sale of Assets | 6.39 | -0.08 | 2.87 | 7.21 | 0.94 | 0.27 | Upgrade
|
Asset Writedown & Restructuring Costs | 49.19 | - | 8.67 | - | - | - | Upgrade
|
Stock-Based Compensation | 8.01 | -2.16 | 326.61 | 67.55 | 52.95 | 80.36 | Upgrade
|
Other Operating Activities | 15 | 17.88 | -1.23 | - | -90.2 | 0.63 | Upgrade
|
Change in Accounts Receivable | 201.07 | 9.33 | -9.06 | 2.19 | -2.52 | -0.72 | Upgrade
|
Change in Inventory | -112.87 | -109.55 | 62.56 | -80.51 | -40.25 | 2.12 | Upgrade
|
Change in Accounts Payable | 4.55 | 1.75 | 33.41 | -15.59 | -66.97 | 32.43 | Upgrade
|
Change in Unearned Revenue | -211.72 | -0.56 | -10.93 | 28.07 | - | - | Upgrade
|
Change in Other Net Operating Assets | -1.32 | 25.3 | -35.98 | 16.82 | 58.67 | -18.88 | Upgrade
|
Operating Cash Flow | -1,145 | -1,151 | -1,435 | -1,334 | -1,387 | -1,788 | Upgrade
|
Capital Expenditures | -80.44 | -105.91 | -71.02 | -93.5 | -29.82 | -66.03 | Upgrade
|
Sale of Property, Plant & Equipment | 1.81 | 0.14 | 6.33 | 1.82 | 6.7 | 0.17 | Upgrade
|
Sale (Purchase) of Intangibles | -3.06 | -4.86 | -0.32 | -2.58 | -0.52 | -1.47 | Upgrade
|
Investment in Securities | 4.7 | - | - | - | - | -193.87 | Upgrade
|
Other Investing Activities | 1,004 | 1.38 | -18.57 | -3.09 | -1.04 | 17.9 | Upgrade
|
Investing Cash Flow | 927 | -109.25 | -83.57 | -97.35 | -24.68 | -243.3 | Upgrade
|
Short-Term Debt Issued | - | 377.65 | - | - | - | - | Upgrade
|
Long-Term Debt Issued | - | - | - | - | - | 94.87 | Upgrade
|
Total Debt Issued | 2.65 | 377.65 | - | - | - | 94.87 | Upgrade
|
Short-Term Debt Repaid | - | -377.65 | - | - | - | - | Upgrade
|
Long-Term Debt Repaid | - | -184.58 | -127.67 | -130.53 | -93.11 | -67.76 | Upgrade
|
Total Debt Repaid | -546.27 | -562.23 | -127.67 | -130.53 | -93.11 | -67.76 | Upgrade
|
Net Debt Issued (Repaid) | -543.62 | -184.58 | -127.67 | -130.53 | -93.11 | 27.11 | Upgrade
|
Issuance of Common Stock | 1,450 | 1,440 | 1,207 | 7.24 | 1,690 | 1,703 | Upgrade
|
Other Financing Activities | -1.5 | - | - | - | - | - | Upgrade
|
Financing Cash Flow | 904.86 | 1,255 | 1,080 | -123.29 | 1,597 | 1,730 | Upgrade
|
Foreign Exchange Rate Adjustments | 5.05 | 0.98 | 33.91 | 117.75 | -31.25 | -58.41 | Upgrade
|
Net Cash Flow | 691.95 | -3.79 | -405.48 | -1,437 | 154.37 | -358.84 | Upgrade
|
Free Cash Flow | -1,225 | -1,257 | -1,506 | -1,427 | -1,417 | -1,854 | Upgrade
|
Free Cash Flow Margin | -1509.42% | -3623.36% | -2452.94% | -6370.97% | -26208.75% | -617884.67% | Upgrade
|
Free Cash Flow Per Share | -6.91 | -8.09 | -11.69 | -12.14 | -13.05 | -20.71 | Upgrade
|
Cash Interest Paid | 51.6 | 53.34 | 57.38 | 54.72 | 45.81 | 17.96 | Upgrade
|
Cash Income Tax Paid | 1.45 | 1.02 | 0.88 | 0.02 | 0.02 | 0.02 | Upgrade
|
Levered Free Cash Flow | -762.96 | -792.54 | -713.06 | -844.23 | -819.13 | -1,075 | Upgrade
|
Unlevered Free Cash Flow | -730.71 | -759.2 | -677.19 | -810.03 | -790.24 | -1,063 | Upgrade
|
Change in Net Working Capital | 129.33 | 87.36 | -55.68 | 59.61 | 56.93 | -15.83 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.